Grace Therapeutics Inc (GRCE) - Long-Term Liabilities to Capital

Grace Therapeutics, Inc. (GRCE) optimizes costs through a virtual management model and the outsourcing of research to external laboratories. The long-term financial debt sustainability metric confirms this approach, with the latest parameter standing at 0.00. Stability is further bolstered by orphan drug sales in Europe and the US, as well as collaborative efforts with scientific foundations to identify therapies for pediatric pathologies.

The indicator is calculated as the ratio of liabilities with a maturity of over one year to the company's equity. This metric determines the degree of financial leverage and the business's dependence on external long-term financing. For Grace Therapeutics, Inc. (GRCE), which is currently in the clinical trial stage, this parameter reflects the cost of investments in future orphan drugs. High leverage is acceptable only if future pricing power is guaranteed. By analyzing the long-term debt-to-equity ratio trend, an investor assesses the stability of the balance sheet structure.